[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-advanced-stage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-advanced-stage":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,78,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100642041","phase-2-sbrt-lattice-pathy-100642041",false,"NCT07645261","SBRT-LATTICE-PATHY","Impact of Partial Stereotactic Body Radiotherapy in Hypoxic Segments of Large-volume Unresectable Tumors (SBRT-LATTICE-PATHY) - a Prospective Phase II Study.","Inclusion Criteria:\n\n* age =or\\> 18 years;\n* Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C 2; benign and malignant tumors for which the use of radiotherapy is well established in the literature;\n* tumors =or\\> 340 cm³ or with a largest diameter =or\\> 7 cm;\n* no indication for any other type of treatment due to lack of proven clinical benefit (surgery, chemotherapy, standard radiotherapy, immunotherapy, targeted therapy, etc.);\n* Palliative Prognostic Index (PPI) =or\\\u003C 2;\n* metastatic disease in the central nervous system (CNS), if present, controlled (up to 3 metastases, each up to 1 cm);\n* up to 5 extracranial distant metastases (nodal or extranodal) =or\\\u003C 5 cm; signed Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* cases in which tumor volume and\u002For the patient's clinical condition make adequate immobilization\u002Fsimulation impossible;\n* previous local radiotherapy;\n* pregnant patients;\n* autoimmune diseases;\n* genetic instability syndromes;\n* ongoing systemic therapy;\n* renal insufficiency that prevents the use of iodinated contrast.","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","To assess the importance of using SBRT-LATTICE-PATHY for the radiotherapy treatment of large tumors that would be considered intractable by currently used standard techniques. In this present study, the investigators will have the possibility of combining SBRT and LATTICE techniques, incorporating the concept of hypoxic tissue irradiation, which are potential modulators of abscopal and bystander effects, performing partial punctual treatment in the vertex region, without the need for irradiation of the entire tissue volume, further improving safety in relation to possible toxicities.",[26,27,28],"Cancer (Advanced Stage)","Cancer (Solid Tumors)","Tumor",[30,31,32,33],"SBRT","LATTICE","partial irradiation","large volume tumors","RECRUITING","2026-06-08",{"date":37,"type":38},"2026-06-12","ACTUAL",{"date":40,"type":38},"2026-04-28",{"date":42,"type":20},"2027-12-31",{"name":44,"class":45},"University of Sao Paulo General Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100643057","pilot-study-of-intermittent-fasting-with-immune-checkpoint-inhibitors-100643057","NCT07645742","Pilot Study of Intermittent Fasting With Immune Checkpoint Inhibitors","Feasibility and Immunometabolic Effects of Intermittent Fasting During Immune Checkpoint Inhibitor Therapy: A Randomized Pilot Study in Advanced Solid Tumors","Inclusion Criteria:\n\n* Diagnosis of advanced esophageal, gastric, non-small cell lung cancer (NSCLC), HCC, cholangiocarcinoma, melanoma, RCC, or MSI-H cancer\n\n  * Planned treatment with ICI-based therapy\n  * ECOG 0-2\n  * Ability to provide informed consent\n  * Willingness to follow dietary guidance and record adherence\n  * BMI = 23-40\n\nExclusion Criteria:\n\n* Diabetes requiring insulin\n\n  * Active eating disorders\n  * Sarcopenia and\u002For cachexia (mild, moderate, severe), including sarcopenic obesity\n  * A history of hypoglycemia, including idiopathic and postbariatric hypoglycemia\n  * Patients taking sulfonylureas (concern for hypoglycemia with fasting)\n  * Night shift workers (at discretion of investigator)\n  * \\>10% weight loss within the past 3 months through self-reporting or chart review.\n  * Any uncontrolled autoimmune condition or recent high-dose steroid use\n  * Severe GI or endocrine disorders precluding fasting including but not limited to malabsorption syndromes, gastroparesis, or Addison's\u002FCushing's\n  * Pregnant or breastfeeding",{"count":55,"type":20},90,[57],"NA","This single-site, randomized pilot study will evaluate whether intermittent fasting is feasible and safe for patients with advanced solid tumors who are starting immune checkpoint inhibitor (ICI) therapy at the WVU Cancer Institute. Participants will be assigned to 1 of 3 groups: usual care with no fasting, alternate-day fasting (ADF), or time-restricted eating (TRE).\n\nParticipants in the ADF group will follow cycles of 12 hours of eating followed by 36 hours of fasting every other day. Participants in the TRE group will eat all daily calories within an 8-hour window each day. The fasting intervention will begin within 1 week of starting ICI treatment and continue for approximately 20-24 weeks during 8 cycles of therapy.\n\nThe study will evaluate adherence to the fasting regimens and compare side effects between groups. Researchers will also study changes in metabolic and immune biomarkers, fatigue, sleep, and quality of life. Participants will be followed for 30 days after completion of the intervention to monitor safety and tolerability.",[26],[61,62,63,64,65,66,67,68,69],"esophogeal","gastric","lung","cholangiocarcinoma","melanoma","Hepatocellular Carcinoma","Immune Checkpoint Inhibitor","Microsatellite Instability-High","Renal Cell Carcinoma","NOT_YET_RECRUITING",{"date":37,"type":38},{"date":73,"type":20},"2026-07",{"date":75,"type":20},"2029-02",{"name":77,"class":45},"West Virginia University",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":46},"100638678","is-the-1939-cancer-act-fit-for-purpose-in-the-modern-technology-era-100638678","NCT07584824","Is the 1939 Cancer Act Fit for Purpose in the Modern Technology Era?","Inclusion Criteria:\n\nPatients\u002FRelatives:\n\n* UK residents (England and Wales ONLY).\n* Have been treated for a cancer within the last three years.\n* Aged 18 or over.\n* Can complete the survey themselves or have it completed on their behalf by a friend or family member (with the patient's permission).\n\nHealthcare Professionals:\n\n* UK-based professionals in the healthcare industry.\n* Working with patients diagnosed with cancer.\n* Consulting with patients at least once a month or more frequently.\n* Aged 18 or over.\n\nExclusion Criteria:\n\nNo explicit exclusion criteria are defined within provided materials, therefore any individual not meeting the inclusion criteria will be excluded.",true,{"count":86,"type":20},50,"OBSERVATIONAL","The 1939 Cancer Act in the UK (England \\& Wales) prohibits advertising of cancer treatments to the public, by anyone but the NHS. The rise of the internet and social media presents new challenges to its enforcement and raises questions about unintended consequences for patients being treated for cancer.\n\nThrough anonymous surveys, this study aims to understand how patients, healthcare professionals and industry professionals perceive technological changes and their implications for online and social media cancer care information, as well as highlight opportunities for safe and ethical modernisation.",[90,91,27,92,26],"Cancer","Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment\u002FCare Regimen; i.e. Curative, Life-extending, or Palliative","Cancer (With or Without Metastasis)","2026-05-07",{"date":95,"type":38},"2026-05-13",{"date":97,"type":38},"2026-01-09",{"date":99,"type":20},"2026-05-30",{"name":101,"class":45},"Royal Cornwall Hospitals Trust",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":112,"studyType":87,"phases":4,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100626286","wellspan-thrive-cancer-qol-study-100626286","NCT07433660","WellSpan-THRIVE Cancer QOL Study","WellSpan Study of Tracking Health and Resilience to Improve the Vitality of Individuals Experiencing Cancer [WellSpan-THRIVE]","THRIVE","Inclusion Criteria:\n\n* Age 18 years and above\n* Primary cancer diagnosis (newly diagnosed within the past 6 months)\n* Able to sign informed consent.\n\nExclusion Criteria:\n\n* Patients with age\\\u003C18 years,\n* Patients with primary non-melanoma skin, neurological malignancies (Brain or brain metastases), and primary hematological malignancies.\n* Patients with severe cognitive impairment, unable to sign informed consent or unable to complete quality of life questionnaire.\n* Patients with life expectancy of \\\u003C90 days, in the opinion of treating investigator.",{"count":111,"type":20},1000,"24 Months","Cancer affects millions of people worldwide and can significantly impact not only survival, but also day-to-day quality of life. Treatments such as surgery, chemotherapy, and radiation can cause side effects like fatigue, pain, and neuropathy, which may affect physical function, emotional well-being, and social relationships. While many studies have examined factors that influence quality of life; such as age, type and stage of cancer, and treatment-related symptoms; there is still a need for tools that more fully reflect patients' lived experiences.\n\nThis study aims to develop and implement a patient-centered quality of life (QOL) survey designed specifically for individuals with cancer. By directly involving patients in sharing what matters most to them, the survey seeks to provide a more complete and accurate understanding of how cancer and its treatment affect daily life. The results will help patients, families, and healthcare providers better identify needs, guide supportive care, and improve overall well-being throughout the cancer journey.",[91,27,92,115,116,26],"Cancer - Ovarian","Cancer Abdomen",[90,118,119,120,121],"Quality of Life","QOL","Registry","Patient","2026-02-26",{"date":124,"type":38},"2026-03-02",{"date":126,"type":20},"2026-02",{"date":128,"type":20},"2031-12",{"name":130,"class":45},"WellSpan Health",5]